CAPR241018C17500
- 1.60
- -1.38-46.31%
Capricor Therapeutics Newsroom
Capricor Therapeutics Analyst Ratings
H.C. Wainwright Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $40
Buy Rating Affirmed for Capricor Therapeutics Amid Promising Developments in DMD-cardiomyopathy Treatment
Oppenheimer Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $43
Oppenheimer Keeps Their Buy Rating on Capricor Therapeutics (CAPR)
A Quick Look at Today's Ratings for Capricor Therapeutics(CAPR.US), With a Forecast Between $25 to $43
Capricor Therapeutics Is Maintained at Buy by Maxim Group
Buy Rating Affirmed for Capricor Therapeutics on Promising DMD-cardiomyopathy Treatment Prospects
HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $40 Price Target
Oppenheimer Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $15
Maxim Group Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $12
Maxim Group Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $12
Oppenheimer Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $15
Capricor Therapeutics Is Maintained at Outperform by Oppenheimer
Capricor Therapeutics Price Target Raised to $15.00/Share From $14.00 by Oppenheimer
Oppenheimer Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Raises Target Price to $15
H.C. Wainwright Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $40
HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $40 Price Target
Capricor Therapeutics Analyst Ratings
Buy Rating Affirmed for Capricor Therapeutics Amidst Expanded Partnership and Regulatory Advancements